CARsgen Therapeutics extends share repurchase, key investor boosts stake

CARsgen Therapeutics Holdings Limited announced the extension of its updated share repurchase plan until the conclusion of its next annual general meeting. This decision, approved by the board, aims to capitalize on what the company believes is an undervalued share price that does not reflect its business prospects. From October 21, 2025, to December 17, 2025, CARsgen repurchased an aggregate of 7,627,000 shares under the 2025 share repurchase mandate. The funds for these repurchases will originate from non-IPO raised sources, including business development income, interest income, and other subsidies.

Concurrently, YIJIE Biotech Holding Limited and its concert parties (the “YIJIE Concert Group”), a substantial shareholder, increased their holdings by purchasing 335,000 shares between November 6, 2025, and December 17, 2025. Following this acquisition, the YIJIE Concert Group now holds 218,283,730 shares, representing approximately 38.2% of the total issued shares (excluding treasury shares).

The board views both the extended share repurchase plan and the increased stake by the substantial shareholder as indicators of confidence in the company's growth prospects and long-term investment value. Shareholders are advised to exercise caution, as the timing, quantity, and price of any future share repurchases will be at the board's discretion and subject to market conditions.